Whole-exome sequencing in relapsing chronic lymphocytic leukemia: Clinical impact of recurrent RPS15 mutations

Blood

Volumn 127, Issue 8, 2016, Pages 1007-1016

  Ljungström, Viktor ^a   Cortese, Diego ^a   Young, Emma ^a   Pandzic, Tatjana ^a   Mansouri, Larry ^a   Plevova, Karla ^b   Ntoufa, Stavroula ^c   Baliakas, Panagiotis ^a   Clifford, Ruth ^d   Sutton, Lesley Ann ^a   Blakemore, Stuart J ^e   Stavroyianni, Niki ^f   Agathangelidis, Andreas ^g   Rossi, Davide ^h   Höglund, Martin ⁱ   Kotaskova, Jana ^b   Juliusson, Gunnar ^j   Belessi, Chrysoula ^k   Chiorazzi, Nicholas ^l   Panagiotidis, Panagiotis ^m   Langerak, Anton W ⁿ   Smedby, Karin E ^o   Oscier, David ^p   Gaidano, Gianluca ^h   Schuh, Anna ^d   Davi, Frederic ^q   Pott, Christiane ^r   Strefford, Jonathan C ^e   Trentin, Livio ^s   Pospisilova, Sarka ^b   Ghia, Paolo ^g   Stamatopoulos, Kostas ^a,c,f   Sjöblom, Tobias ^a   Rosenquist, Richard ^a   more..

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^c INFORMATION TECHNOLOGIES INSTITUTE   (Greece)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^f G PAPANICOLAOU HOSPITAL   (Greece)

^g SAN RAFFAELE HOSPITAL   (Italy)

^h UNIVERSITY OF EASTERN PIEDMONT   (Italy)

ⁱ UPPSALA UNIVERSITY   (Sweden)

^j LUND UNIVERSITY   (Sweden)

^k GENERAL HOSPITAL OF NIKEA   (Greece)

^l FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^m UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

ⁿ ERASMUS MEDICAL CENTER   (Netherlands)

^o KAROLINSKA INSTITUTE   (Sweden)

^p ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^q SORBONNE UNIVERSITÉ   (France)

^r UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^s UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; CYCLOPHOSPHAMIDE; FLUDARABINE; NOTCH1 RECEPTOR; PROTEIN P53; RITUXIMAB; ANTINEOPLASTIC AGENT; RIBOSOMAL PROTEIN S15; RIBOSOME PROTEIN; VIDARABINE;

ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; EXOME; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN STABILITY; ANALOGS AND DERIVATIVES; CELL SEPARATION; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE; GENETIC TRANSFECTION; GENETICS; IMMUNOPRECIPITATION; KAPLAN MEIER METHOD; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MISSENSE MUTATION; MORTALITY; PATHOLOGY; TUMOR RECURRENCE; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CELL SEPARATION; CYCLOPHOSPHAMIDE; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; EXOME; HUMANS; IMMUNOPRECIPITATION; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MUTATION, MISSENSE; NEOPLASM RECURRENCE, LOCAL; RIBOSOMAL PROTEINS; RITUXIMAB; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; VIDARABINE;

EID: 84960461460     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-10-674572     Document Type: Article

References (34)

1. Hallek M, Fischer K, Fingerle-Rowson G, et al; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, openlabel, phase 3 trial. Lancet. 2010;376(9747): 1164-1174.
2. Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4070-4078.
3. Sutton LA, Rosenquist R. Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution. Haematologica. 2015;100(1):7-16.
4. Puente XS, Pinyol M, Quesada V, et al. Wholegenome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011; 475(7354):101-105.
5. Fabbri G, Rasi S, Rossi D, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med. 2011;208(7):1389-1401.
6. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011;365(26): 2497-2506.
7. Quesada V, Conde L, Villamor N, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet. 2012;44(1):47-52.
8. Rossi D, Fangazio M, Rasi S, et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood. 2012;119(12): 2854-2862.
9. Messina M, Del Giudice I, Khiabanian H, et al. Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness. Blood. 2014;123(15):2378-2388.
10. Damm F, Mylonas E, Cosson A, et al. Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov. 2014;4(9): 1088-1101.
11. Mansouri L, Sutton LA, Ljungström V, et al. Functional loss of IkBe leads to NF-kB deregulation in aggressive chronic lymphocytic leukemia. J Exp Med. 2015;212(6): 833-843.
12. Baliakas P, Hadzidimitriou A, Sutton LA, et al; European Research Initiative on CLL (ERIC). Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia. 2015;29(2): 329-336.
13. Sutton LA, Ljungström V, Mansouri L, et al. Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting. Haematologica. 2015;100(3): 370-376.
14. Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013;152(4): 714-726.
15. Schuh A, Becq J, Humphray S, et al. Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. Blood. 2012;120(20):4191-4196.
16. Rossi D, Khiabanian H, Spina V, et al. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood. 2014; 123(14):2139-2147.
17. Malcikova J, Stano-Kozubik K, Tichy B, et al. Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia. Leukemia. 2015;29(4): 877-885.
18. Daftuar L, Zhu Y, Jacq X, Prives C. Ribosomal proteins RPL37, RPS15 and RPS20 regulate the Mdm2-p53-MdmX network. PLoS One. 2013;8(7): e68667.
19. Hallek M, Cheson BD, Catovsky D, et al; International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12): 5446-5456.
20. Catovsky D, Richards S, Matutes E, et al; UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group; NCRI Chronic Lymphocytic Leukaemia Working Group. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007; 370(9583):230-239.
21. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics. 2010;26(5):589-595.
22. DePristo MA, Banks E, Poplin R, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43(5):491-498.
23. Koboldt DC, Zhang Q, Larson DE, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012;22(3):568-576.
24. Magi A, Tattini L, Cifola I, et al. EXCAVATOR: detecting copy number variants from wholeexome sequencing data. Genome Biol. 2013; 14(10):R120.
25. Miller CA, White BS, Dees ND, et al. SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. PLOS Comput Biol. 2014;10(8): e1003665.
26. Edelmann J, Holzmann K, Miller F, et al. High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. Blood. 2012;120(24): 4783-4794.
27. De Paoli L, Cerri M, Monti S, et al. MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia. Leuk Lymphoma. 2013;54(5):1087-1090.
28. Landau DA, Tausch E, Taylor-Weiner AN, et al. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015; 526(7574):525-530.
29. Oscier DG, Rose-Zerilli MJ, Winkelmann N, et al. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood. 2013; 121(3):468-475.
30. Aparicio S, Caldas C. The implications of clonal genome evolution for cancer medicine. N Engl J Med. 2013;368(9):842-851.
31. Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012; 481(7382):506-510.
32. Guièze R, Robbe P, Clifford R, et al. Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL. Blood. 2015; 126(18):2110-2117.
33. De Keersmaecker K, Atak ZK, Li N, et al. Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. Nat Genet. 2013;45(2): 186-190.
34. Rao S, Lee SY, Gutierrez A, et al. Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B. Blood. 2012;120(18): 3764-3773.